Correction to: *Scientific Reports* 10.1038/s41598-017-02279-x, published online 17 May 2017

The Article contains errors.

Reference 12 is cited to support a statement that YB-1 is up-regulated in different cancers, and that YB-1 overexpression is linked to adverse clinical outcomes. However, this reference reports that the results are dependent on the antibody against YB-1. As such the authors do not think its citation in the original text is appropriate and wish to remove it.

As a result, in the Introduction,

"Given the "oncogenic" nature of these functions, it is not unexpected that up-regulation of YB-1 has been reported in virtually all human cancer types, including epithelial and mesenchymal solid cancers^7,8,9,10,11,12,13,14,15,16^ as well as haematological diseases like lymphoma and leukaemia^17,18^. YB-1 overexpression has been linked to adverse clinical outcome and poor therapy response in most of them^7,8,9,10,11,12,14,15,17,18^, making it a promising prognostic biomarker in cancer."

should read:

"Given the "oncogenic" nature of these functions, it is not unexpected that up-regulation of YB-1 has been reported in virtually all human cancer types, including epithelial and mesenchymal solid cancers^7,8,9,10,11,13,14,15,16^ as well as haematological diseases like lymphoma and leukaemia^17,18^. YB-1 overexpression has been linked to adverse clinical outcome and poor therapy response in most of them^7,8,9,10,11,14,15,17,18^, making it a promising prognostic biomarker in cancer."

Additionally, the following sentence citing this reference should be included in the Materials and Methods section, under the subheading 'Immunochemistry':

"Of note, this antibody has been shown to detect an epitope also present on heterogeneous nuclear ribonucleoprotein A1 (Wooley *et al*.^12^)."
